Landmark COPD study shows benefits of triple vs dual therapy

What the IMPACT trial means for patients


GSK Logo

This content was produced by Australian Doctor Group with GSK.

Doctors regularly manage patients who have COPD exacerbations despite dual therapy but, until recently, the benefits of stepping up to triple therapy had not been comprehensively evaluated.1

The landmark IMPACT trial, published in The New England Journal of Medicine, evaluated a new once-daily single-inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) compared with dual therapy.1,2

IMPACT compared Trelegy